Metabolomics Analysis Reveals Interaction of Base-Line Chemotherapy and Shiyiwei Shenqi Tablets in Breast Cancer Treatment

• Main Authors: Hong Wan, Xiaojun Xu, Xiaowei Yang, Angqing Li, Xiaopeng Ma, Aman Xu, Xiao Yuan, Wenbin Wang, Tao Guo, Guangtao Luo, Xiaobo He, Wang Li, Zhaorui Wang, Qiang Sun, Jing Pei, Yongzhen Guo, Yong Zhu
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-09-01
• Series: Frontiers in Pharmacology
• Subjects: shiyiwei shenqi tablets; breast cancer; untargeted metabolomics; amino acid metabolism; side effects
• Online Access: https://www.frontiersin.org/articles/10.3389/fphar.2021.720886/full

Shiyiwei Shenqi Tablet (SSTs) has been widely used for treatment of different types of cancer including breast cancer. SST has drawn more and more interest due to the low rate of side effects. The aim of this study was to investigate the metabolites in serums of breast cancer patients who received base-line chemotherapy only or combination treatment with SST. An untargeted metabolomics method was developed to investigate the alteration of metabolism in patients’ serums using ultra-high-performance liquid chromatography/Q-exactive Orbitrap mass spectrometry. The patients were separated based on the metabolomics data, and further analyses showed that SST treatment can affect the metabolism of glucose, fatty acid, bile acid and amino acid. In particular, SST treatment significantly reduced some short peptides which are potential tumor neoantigens. This study may provide novel insights into the mechanism underlying interaction between SST and base-line chemotherapy in terms of affecting metabolic pathways and thereby changing metabolic products, which might shed new light for clinical medication.